ONO 1505

Drug Profile

ONO 1505

Alternative Names: ONO BF11301

Latest Information Update: 11 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ono Pharmaceutical; Scherer Healthcare
  • Class Anti-ischaemics; Imidazoles; Small molecules; Vasodilators
  • Mechanism of Action Thromboxane synthase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic complications; Ischaemic heart disorders

Most Recent Events

  • 08 Jun 2001 No-Development-Reported for Diabetic complications in United Kingdom (Unknown route)
  • 09 Jul 1998 Biofor is now part of Scherer Healthcare
  • 16 May 1997 Preclinical development for Diabetic complications in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top